Dernières nouvelles pour Enveric Biosciences (NASDAQ:ENVB) Stock

Enveric Biosciences

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. The company's lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.

Enveric Biosciences Inc

<p><strong>Mercury Sys</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRCY#NASDAQ">MRCY</a>) released its Q2 earnings on Tuesday, February 4, 2025 at 04:01 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Mercury Sys beat estimated earnings by 275.0%, reporting an EPS of $0.07 versus an estimate of $-0.04.</p>
<p>Revenue was up $25.66 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>Last quarter the company beat on EPS by $0.12 which was followed by a 23.0% increase in the share price the next day.</p>
<p>Here's a look at Mercury Sys's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.08</td>
<td>0.02</td>
<td>-0.03</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.04</td>
<td>0.23</td>
<td>-0.26</td>
<td>-0.42</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>181.77M</td>
<td>230.69M</td>
<td>214.07M</td>
<td>214.44M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>204.43M</td>
<td>248.56M</td>
<td>208.26M</td>
<td>197.46M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Mercury Sys <a href="https://www.benzinga.com/quote/MRCY/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings

MRCY

Recap: Mercury Sys Q2 Earnings

<p><strong>Omnicom Group</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMC#NYSE">OMC</a>) just disclosed its Q4 earnings on Tuesday, February 4, 2025 at 04:03 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Omnicom Group beat estimated earnings by 1.0%, reporting an EPS of $2.41 versus an estimate of $2.39.</p>
<p>Revenue was up $261.00 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company beat on EPS by $0.01 in the previous quarter, leading to a 1.0% increase share price change the next day.</p>
<p>Here's a look at Omnicom Group's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.02</td>
<td>1.93</td>
<td>1.55</td>
<td>2.21</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.03</td>
<td>1.95</td>
<td>1.67</td>
<td>2.20</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>3.80B</td>
<td>3.82B</td>
<td>3.62B</td>
<td>4.00B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.88B</td>
<td>3.85B</td>
<td>3.63B</td>
<td>4.06B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Omnicom Group <a href="https://www.benzinga.com/quote/OMC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: Omnicom Group Q4 Earnings

<p><strong>Oscar Health</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OSCR#NYSE">OSCR</a>) announced its Q4 earnings on Tuesday, February 4, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Oscar Health missed estimated earnings by -7.000000000000001%, reporting an EPS of $-0.62 versus an estimate of $-0.58.</p>
<p>Revenue was up $960.00 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>In the previous quarter, the company missed on EPS by $0.05, resulting in a 1.0% drop change in the share price the following day.</p>
<p>Here's a look at Oscar Health's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.17</td>
<td>0.15</td>
<td>0.27</td>
<td>-0.72</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.22</td>
<td>0.20</td>
<td>0.62</td>
<td>-0.66</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>2.34B</td>
<td>2.17B</td>
<td>2.01B</td>
<td>1.42B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>2.42B</td>
<td>2.22B</td>
<td>2.14B</td>
<td>1.43B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Oscar Health <a href="https://www.benzinga.com/quote/OSCR/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


OSCR

Oscar Health: Q4 Earnings Insights

<p>The Q4 earnings report for <strong>FMC</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) was released on Tuesday, February 4, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>FMC beat estimated earnings by 12.0%, reporting an EPS of $1.79 versus an estimate of $1.6.</p>
<p>Revenue was up $78.00 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>The company beat on EPS by $0.16 in the previous quarter, leading to a 11.0% increase share price change the next day.</p>
<p>Here's a look at FMC's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.53</td>
<td>0.57</td>
<td>0.34</td>
<td>1.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.69</td>
<td>0.63</td>
<td>0.36</td>
<td>1.07</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.04B</td>
<td>1.05B</td>
<td>1.01B</td>
<td>1.25B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.06B</td>
<td>1.04B</td>
<td>918.00M</td>
<td>1.15B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>FMC management provided guidance for Q1 2025, expecting earnings between $0.05 and $0.15 per share.</p>
<p>To track all earnings releases for FMC <a href="https://www.benzinga.com/quote/FMC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Recap: FMC Q4 Earnings

<p>The earnings results for <strong>Varonis Systems</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNS#NASDAQ">VRNS</a>) for Q4 were made public on Tuesday, February 4, 2025 at 04:05 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Varonis Systems beat estimated earnings by 28.999999999999996%, reporting an EPS of $0.18 versus an estimate of $0.14.</p>
<p>Revenue was up $4.42 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.03, leading to a 11.0% drop share price change the next day.</p>
<p>Here's a look at Varonis Systems's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.07</td>
<td>-0.02</td>
<td>-0.09</td>
<td>0.23</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.10</td>
<td>0.05</td>
<td>-0.03</td>
<td>0.27</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>141.64M</td>
<td>124.86M</td>
<td>113.62M</td>
<td>151.83M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>148.07M</td>
<td>130.35M</td>
<td>114.02M</td>
<td>154.10M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Varonis Systems management provided guidance for FY 2025, expecting earnings between $0.13 and $0.17 per share.</p>
<p>To track all earnings releases for Varonis Systems <a href="https://www.benzinga.com/quote/VRNS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VRNS

Earnings Breakdown: Varonis Systems Q4

<p><strong>Aviat Networks</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVNW#NASDAQ">AVNW</a>) reported its Q2 earnings results on Tuesday, February 4, 2025 at 04:01 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Aviat Networks beat estimated earnings by 1267.0%, reporting an EPS of $0.82 versus an estimate of $0.06.</p>
<p>Revenue was up $23.16 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>During the previous quarter, the company missed on EPS by $0.84, leading to a 35.0% drop share price change the next day.</p>
<p>Here's a look at Aviat Networks's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.03</td>
<td>0.69</td>
<td>0.51</td>
<td>0.87</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.87</td>
<td>0.72</td>
<td>0.73</td>
<td>0.97</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>94.21M</td>
<td>112.92M</td>
<td>113.44M</td>
<td>91.47M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>88.43M</td>
<td>116.66M</td>
<td>111.61M</td>
<td>95.04M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Aviat Networks <a href="https://www.benzinga.com/quote/AVNW/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AVNW

Aviat Networks Earnings Review: Q2 Summary

<p><strong>Hanover Insurance Gr</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THG#NYSE">THG</a>) released its Q4 earnings on Tuesday, February 4, 2025 at 04:10 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Hanover Insurance Gr beat estimated earnings by 56.99999999999999%, reporting an EPS of $5.32 versus an estimate of $3.39.</p>
<p>Revenue was up $99.00 million from the same period last year.</p>
<h3>Earnings History Overview</h3>
<p>In the previous quarter, the company beat on EPS by $0.52, resulting in a 2.0% drop change in the share price the following day.</p>
<p>Here's a look at Hanover Insurance Gr's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.53</td>
<td>1.57</td>
<td>2.71</td>
<td>2.73</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.05</td>
<td>1.88</td>
<td>3.08</td>
<td>3.13</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.67B</td>
<td>1.49B</td>
<td>1.47B</td>
<td>1.41B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.48B</td>
<td>1.47B</td>
<td>1.45B</td>
<td>1.35B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Hanover Insurance Gr <a href="https://www.benzinga.com/quote/THG/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Hanover Insurance Gr Earnings Analysis: Q4 Recap

<p><strong>Enact Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACT#NASDAQ">ACT</a>) just disclosed its Q4 earnings on Tuesday, February 4, 2025 at 04:15 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>Enact Holdings beat estimated earnings by 6.0%, reporting an EPS of $1.09 versus an estimate of $1.03.</p>
<p>Revenue was up $5.59 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>During the previous quarter, the company beat on EPS by $0.15, leading to a 2.0% drop share price change the next day.</p>
<p>Here's a look at Enact Holdings's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.01</td>
<td>0.98</td>
<td>0.96</td>
<td>0.92</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.16</td>
<td>1.27</td>
<td>1.04</td>
<td>0.98</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>309.26M</td>
<td>298.83M</td>
<td>294.12M</td>
<td>299.81M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>309.59M</td>
<td>298.83M</td>
<td>291.58M</td>
<td>296.19M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Enact Holdings <a href="https://www.benzinga.com/quote/ACT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Breakdown: Enact Holdings Q4

<p><strong>Unum Gr</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNM#NYSE">UNM</a>) reported its Q4 earnings results on Tuesday, February 4, 2025 at 04:15 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Unum Gr missed estimated earnings by -5.0%, reporting an EPS of $2.03 versus an estimate of $2.14.</p>
<p>Revenue was up $92.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.03 which was followed by a 4.0% increase in the share price the next day.</p>
<p>Here's a look at Unum Gr's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.10</td>
<td>2.02</td>
<td>1.97</td>
<td>1.86</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.13</td>
<td>2.16</td>
<td>2.12</td>
<td>1.79</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>3.26B</td>
<td>3.23B</td>
<td>3.21B</td>
<td>3.14B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.22B</td>
<td>3.23B</td>
<td>3.20B</td>
<td>3.15B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Unum Gr management provided guidance for FY 2025, expecting earnings between $9.12 and $9.45 per share.</p>
<p>To track all earnings releases for Unum Gr <a href="https://www.benzinga.com/quote/UNM/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Unum Gr Earnings Report: Q4 Overview

<p><strong>Mattel</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) announced its Q4 earnings on Tuesday, February 4, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Mattel beat estimated earnings by 75.0%, reporting an EPS of $0.35 versus an estimate of $0.2.</p>
<p>Revenue was up $25.00 million from the same period last year.</p>
<h3>Previous Earnings Records</h3>
<p>The company beat on EPS by $0.19 in the last quarter, resulting in a 4.0% increase share price change the following day.</p>
<p>Here's a look at Mattel's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.95</td>
<td>0.17</td>
<td>-0.13</td>
<td>0.32</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.14</td>
<td>0.19</td>
<td>-0.05</td>
<td>0.29</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.86B</td>
<td>1.10B</td>
<td>831.80M</td>
<td>1.66B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.84B</td>
<td>1.08B</td>
<td>809.50M</td>
<td>1.62B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Mattel management provided guidance for FY 2025, expecting earnings between $1.66 and $1.72 per share.</p>
<p>To track all earnings releases for Mattel <a href="https://www.benzinga.com/quote/MAT/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Earnings Summary: Mattel Q4

WIIM

DKNG

DraftKings shares are trading higher after Robinhood received a formal request from the CFTC to roll back the pro football championship market.

<p>The Q4 earnings report for <strong>Columbia Sportswear</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLM#NASDAQ">COLM</a>) was released on Tuesday, February 4, 2025 at 04:05 PM.</p>
<p>Here's what investors need to know about the latest announcement.</p>
<h3>Earnings</h3>
<p>Columbia Sportswear missed estimated earnings by -4.0%, reporting an EPS of $1.8 versus an estimate of $1.88.</p>
<p>Revenue was up $37.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.2 which was followed by a 6.0% increase in the share price the next day.</p>
<p>Here's a look at Columbia Sportswear's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.36</td>
<td>-0.34</td>
<td>0.35</td>
<td>1.96</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.56</td>
<td>-0.20</td>
<td>0.71</td>
<td>1.86</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>936.33M</td>
<td>568.29M</td>
<td>740.02M</td>
<td>1.08B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>931.77M</td>
<td>570.24M</td>
<td>769.98M</td>
<td>1.06B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Columbia Sportswear management provided guidance for FY 2025, expecting earnings between $3.8 and $4.15 per share.</p>
<p>To track all earnings releases for Columbia Sportswear <a href="https://www.benzinga.com/quote/COLM/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


COLM

Insights into Columbia Sportswear Q4 Earnings

<p><strong>DXC Technology</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) just disclosed its Q3 earnings on Tuesday, February 4, 2025 at 04:15 PM.</p>
<p>Here's a brief overview of the earnings report.</p>
<h3>Earnings</h3>
<p>DXC Technology beat estimated earnings by 19.0%, reporting an EPS of $0.92 versus an estimate of $0.77.</p>
<p>Revenue was down $174.00 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company beat on EPS by $0.21 in the previous quarter, leading to a 4.0% drop share price change the next day.</p>
<p>Here's a look at DXC Technology's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2025</strong></th>
<th><strong>Q1 2025</strong></th>
<th><strong>Q4 2024</strong></th>
<th><strong>Q3 2024</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.72</td>
<td>0.58</td>
<td>0.83</td>
<td>0.77</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.93</td>
<td>0.74</td>
<td>0.97</td>
<td>0.87</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>3.20B</td>
<td>3.13B</td>
<td>3.37B</td>
<td>3.36B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>3.24B</td>
<td>3.24B</td>
<td>3.39B</td>
<td>3.40B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>DXC Technology management provided guidance for Q4 2025, expecting earnings between $0.75 and $0.75 per share.</p>
<p>To track all earnings releases for DXC Technology <a href="https://www.benzinga.com/quote/DXC/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


DXC Technology Earnings Review: Q3 Summary

<p><strong>Zurn Elkay Water</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZWS#NYSE">ZWS</a>) reported its Q4 earnings results on Tuesday, February 4, 2025 at 04:10 PM.</p>
<p>Here's what investors need to know about the announcement.</p>
<h3>Earnings</h3>
<p>Zurn Elkay Water beat estimated earnings by 14.000000000000002%, reporting an EPS of $0.32 versus an estimate of $0.28.</p>
<p>Revenue was up $13.90 million from the same period last year.</p>
<h3>Historical Earnings Summary</h3>
<p>During the previous quarter, the company beat on EPS by $0.02, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Zurn Elkay Water's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.32</td>
<td>0.31</td>
<td>0.26</td>
<td>0.23</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.34</td>
<td>0.33</td>
<td>0.29</td>
<td>0.26</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>405.84M</td>
<td>408.38M</td>
<td>368.99M</td>
<td>350.45M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>410.00M</td>
<td>412.00M</td>
<td>373.80M</td>
<td>356.80M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Zurn Elkay Water <a href="https://www.benzinga.com/quote/ZWS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Zurn Elkay Water Earnings Review: Q4 Summary

<p><strong>Ichor Hldgs</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICHR#NASDAQ">ICHR</a>) announced its Q4 earnings on Tuesday, February 4, 2025 at 04:05 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Ichor Hldgs missed estimated earnings by -27.0%, reporting an EPS of $0.08 versus an estimate of $0.11.</p>
<p>Revenue was up $29.81 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>In the previous quarter, the company beat on EPS by $0.01, resulting in a 16.0% increase change in the share price the following day.</p>
<p>Here's a look at Ichor Hldgs's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.11</td>
<td>0.03</td>
<td>0</td>
<td>0.07</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.12</td>
<td>0.05</td>
<td>-0.09</td>
<td>-0.06</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>203.27M</td>
<td>197.57M</td>
<td>199.99M</td>
<td>197.50M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>211.14M</td>
<td>203.23M</td>
<td>201.38M</td>
<td>203.48M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Ichor Hldgs management provided guidance for Q1 2025, expecting earnings between $0.2 and $0.32 per share.</p>
<p>To track all earnings releases for Ichor Hldgs <a href="https://www.benzinga.com/quote/ICHR/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ICHR

Ichor Hldgs Q4 Earnings Assessment

News

Guidance

MTCH

Match Group Sees Q1 Revenue $820M-$830M Vs $853.091M Est.

<p><strong>Enova International</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>) announced its Q4 earnings on Tuesday, February 4, 2025 at 04:16 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Enova International beat estimated earnings by 15.0%, reporting an EPS of $2.61 versus an estimate of $2.27.</p>
<p>Revenue was up $145.96 million from the same period last year.</p>
<h3>Overview of Past Earnings</h3>
<p>The company beat on EPS by $0.14 in the last quarter, resulting in a 2.0% drop share price change the following day.</p>
<p>Here's a look at Enova International's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>2.31</td>
<td>2.07</td>
<td>1.72</td>
<td>1.66</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>2.45</td>
<td>2.21</td>
<td>1.91</td>
<td>1.83</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>666.33M</td>
<td>622.93M</td>
<td>584.42M</td>
<td>586.33M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>689.92M</td>
<td>628.44M</td>
<td>609.89M</td>
<td>583.59M</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Enova International <a href="https://www.benzinga.com/quote/ENVA/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


ENVA

Enova International Earnings Report: Q4 Overview

<p><strong>Essex Property Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESS#NYSE">ESS</a>) announced its Q4 earnings on Tuesday, February 4, 2025 at 04:15 PM.</p>
<p>Here's a breakdown of the earnings report.</p>
<h3>Earnings</h3>
<p>Essex Property Trust beat estimated earnings by 1.0%, reporting an EPS of $3.92 versus an estimate of $3.9.</p>
<p>Revenue was up $41.72 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>The company beat on EPS by $0.03 in the last quarter, resulting in a 1.0% drop share price change the following day.</p>
<p>Here's a look at Essex Property Trust's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>3.88</td>
<td>3.85</td>
<td>3.74</td>
<td>3.81</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>3.91</td>
<td>3.94</td>
<td>3.83</td>
<td>3.83</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>445.88M</td>
<td>431.82M</td>
<td>422.38M</td>
<td>419.74M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>450.70M</td>
<td>442.36M</td>
<td>426.93M</td>
<td>412.75M</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Essex Property Trust management provided guidance for FY 2025, expecting earnings between $15.56 and $16.06 per share.</p>
<p>To track all earnings releases for Essex Property Trust <a href="https://www.benzinga.com/quote/ESS/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Essex Property Trust Q4 Earnings

<p><strong>Juniper Networks</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNPR#NYSE">JNPR</a>) released its Q4 earnings on Tuesday, February 4, 2025 at 04:15 PM.</p>
<p>Here's what's important from the earnings announcement.</p>
<h3>Earnings</h3>
<p>Juniper Networks beat estimated earnings by 12.0%, reporting an EPS of $0.64 versus an estimate of $0.57.</p>
<p>Revenue was up $39.00 million from the same period last year.</p>
<h3>Analysis of Past Earnings</h3>
<p>The company beat on EPS by $0.04 in the previous quarter, leading to a 0.0% increase share price change the next day.</p>
<p>Here's a look at Juniper Networks's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.44</td>
<td>0.44</td>
<td>0.40</td>
<td>0.64</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.48</td>
<td>0.31</td>
<td>0.29</td>
<td>0.61</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.26B</td>
<td>1.25B</td>
<td>1.24B</td>
<td>1.41B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.33B</td>
<td>1.19B</td>
<td>1.15B</td>
<td>1.36B</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Juniper Networks <a href="https://www.benzinga.com/quote/JNPR/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


JNPR

Earnings Breakdown: Juniper Networks Q4

<p>The earnings results for <strong>Veralto</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLTO#NYSE">VLTO</a>) for Q4 were made public on Tuesday, February 4, 2025 at 04:30 PM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Veralto beat estimated earnings by 7.000000000000001%, reporting an EPS of $0.95 versus an estimate of $0.89.</p>
<p>Revenue was up $57.00 million from the same period last year.</p>
<h3>Past Earnings Performance</h3>
<p>Last quarter the company beat on EPS by $0.04 which was followed by a 5.0% drop in the share price the next day.</p>
<p>Here's a look at Veralto's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.85</td>
<td>0.80</td>
<td>0.76</td>
<td>0.81</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.89</td>
<td>0.85</td>
<td>0.84</td>
<td>0.87</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>1.30B</td>
<td>1.28B</td>
<td>1.23B</td>
<td>1.25B</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>1.31B</td>
<td>1.29B</td>
<td>1.25B</td>
<td>1.29B</td>
</tr>
</tbody>
</table>
</p>
<p>New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).</p>
<h3>Guidance</h3>
<p>Veralto management provided guidance for FY 2025, expecting earnings between $3.6 and $3.7 per share.</p>
<p>To track all earnings releases for Veralto <a href="https://www.benzinga.com/quote/VLTO/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VLTO

Veralto Earnings Analysis: Q4 Recap

Psychedelic drug developer Lykos could get lifeline from former Tesla board member

17:11 EST Enveric Biosciences (ENVB) files to sell common stock, warrants, no amount given Published first on TheFly – the ultimate source for real...

Enveric Biosciences files to sell common stock, warrants, no amount given

Enveric Biosciences announces offering of common stock and warrants

19:50 EST Enveric Biosciences (ENVB) trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving brea...

Enveric Biosciences trading halted, news pending

The company states: Enveric Biosciences (ENVB) announced that it has received a Notice of Allowance from the United States Patent and Trademark Off...

Enveric Biosciences gets Notice of Allowance for EB-003 from USPTO

H.C. Wainwright is acting as sole book running manager for the offering. Published first on TheFly – the ultimate source for real-time, market-movi...

Enveric Biosciences 1.67M share Spot Secondary priced at $3.00

Enveric Biosciences stock plummets after pricing $5M capital raise

Enveric Biosciences (ENVB) announces that its wholly-owned subsidiary, Akos Biosciences has entered into two licensing agreements with Restoration ...

Enveric Biosciences unit in licensing pacts with Restoration Biologics

Enveric Biosciences and Restoration Biologics signs licensing agreements to treat joint disease

ATAI

ATNF

CMND

CMPS

CYBN

DRUG

ENVB

GHRS

MNMD

SPRC

Doctor,Hand,Holding,A,Holographic,Of,Human,Brain,In,Healthcare

Biotech

Enveric Biosciences Presents Compelling Preclinical Data On Lead Compound EB-003 At 7th Neuropsychiatric Drug Summit

Press Releases

Enveric Biosciences Announces Broad Range of Patent Issuances

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2025"

Comments

Enveric Biosciences

Actualités

Dernières nouvelles pour Enveric Biosciences (NASDAQ:ENVB) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL